Study On Myelodysplastic Syndrome T Lymphocyte Immune Abnormalities And Cyclosporin A Intervention Therapy

Objective:The myelodysplastic syndromes (MDS) constitute a group of heterogeneous clonal haemopoietic stem cell disorders, characterized by ineffective and dysplastic haematopoiesis with varying degrees of refractory peripheral cytopenia,as well as by an increased risk of evolution towards acute myeloid leukaemia.The clinical manifestations difference is large, there is no standardized and effective standard treatment, most people think that MDS pathogenesis and immune abnormalities, but each subtype immune alterations are not consistent, the immune response modifier is not the same. To investigate the expression of Th22lymphocytes and Th17lymphocytes in peripheral blood of myelodysplasfic syndromes, so that exploring the cellular immune transform of MDS, and in MDS patients.analyzing the significance of the clinical types and stages. It. analysis the effects of cyclosporine trestment on immune function in different stages of MDS.Methods:Collected during2012July to2013December22cases of newly diagnosed MDS patients and15healthy controls, all cases were confirmed by blood, bone marrow, chromosome, FISH, genetic and other checks and meet the diagnostic criteria of Vienna. According to the WHO (2008)"hematopoietic and lymphoid tissue tumor classification "in the diagnostic criteria for staging. MDS typing methods of using Fluorescein-labeled monoclonal antibodies, The expression of Th17lymphocytes and Th22lymphocytes by Flow eytometry(FCM) investigate, and with the period between MDS. Observe change of immune abnormalities the different stages of patients with MDS Th, Ts lymphocyte subsets before and after6months of treatment in the application of cyclosporine-based immunosuppressive regimen.Results:The percentage of Th22with treatment-primary [(4.18±1.52)%ratio (4.15±1.63)%] in peripheml blood of patients. MDS was slightly higher.was not statistically significant [(0.69±0.22)%ratio (0.75±0.37),(P<0.05)], and the percentage of Th17cells with treatment-primary MDS was significantly decreased(P<0.05) in peripheral blood of patients, the percentage of Th22of patients in MDS-RAEB and RCMD group was significantly higher than the patients in MDS-RA/RARS group, the differences were statistically significant(P<0.05). the percentage of Th22of patients in MDS-RA/RARS and RCMD group was significantly lower than the patients in MDS-RAEB group(P<0.05), However Th17cells have no statistical difference compare to any groups (P>0.05). The MDS group Th cells, Th/Ts ratio were lower than those in normal control group [(36.02±4.13)%ratio (48.21±1.05)%,(1.74±0.78)%ratio (2.16±0.47)%](P<0.05). the differences were statistically significant(P<0.05). Ts cells express higher than that in normal control group [(27.34±7.28)%ratio (20.80±3.63)%, the differences were statistically significant(P<0.05). Before and after treatment of Th cells, Th/Ts ratio, Ts cells of T lymphocyte subset were significant difference [After treatment, respectively(39.09±3.92)%,(24.13±3.54)%,(1.95±0.92)%, P<0.05)].Conclusion:Th22and Thl7cells detection in MDS was helpful to evaluate the clinical stages to guide the clinical classification, clinical treatment. It is important to predict cyclosporine efficacy.